If you've spent any time testing AI video tools, you've probably noticed a pattern: most of them are built for short bursts.

Muse Image, which can create realistic images for users on Instagram and WhatsApp, is the company’s latest attempt to catch up in the global artificial intelligence race. By Eli Tan Reporting from San ...

If you have an idea for a non-fiction book, Youbooks AI Non-Fiction Book Generator can make it happen in a matter of hours.

Comedy is subjective, but some movies have managed to make generations of viewers laugh for decades, from the slapstick stuff ...

The dancers had used music generated by AI. Whatever model was involved had likely been trained on “You Get What You Give” ...

The planet’s 2,640 billionaires are worth $12.2 trillion. Here’s who’s up, who’s down and who’s off the list. The party is over for many of the world’s richest people. For the second straight year, ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...